Companies: 10,795·Total market cap: $144.5T
Better Therapeutics, Inc.

Better Therapeutics, Inc.

BTTXOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$5452
P/E Ratio
52W High$0.001
52W Low$0.0001

Better Therapeutics, Inc. (BTTX) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

bttx · pe ratio · data through Dec 31, 2022

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Better Therapeutics, Inc. (BTTX) measures how much investors pay for each dollar of the company's trailing earnings. BTTX's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$1.69.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31

Forward P/E
N/A
FY2026 est. EPS $-0.69
Based on 1 analyst
EPS (TTM)
-$1.69
TTM · diluted EPS
PEG Ratio
-0.00
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Better Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2019 – 2022 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Better Therapeutics, Inc.
Better Therapeutics, Inc.You
BTTX
$0MN/A-$1.69
Ampio Pharmaceuticals, Inc.
Ampio Pharmaceuticals, Inc.
AMPE
$0MN/A-$10.67
Arno Therapeutics, Inc.
Arno Therapeutics, Inc.
ARNI
$0MN/A-$0.57
Baudax Bio, Inc.
Baudax Bio, Inc.
BXRXQ
$0MN/A-$177.30
Calithera Biosciences, Inc.
Calithera Biosciences, Inc.
CALA
$0MN/A-$3.78
Kaleido Biosciences, Inc.
Kaleido Biosciences, Inc.
KLDO
$0MN/A-$2.16
Oncology Pharma Inc.
Oncology Pharma Inc.
ONPH
$2MN/A-$0.00

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 4 of 4 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2022-12-31Latest
FY2022
$-1.69
2021-12-31
FY2021
$-1.71
2020-12-31
FY2020
$-0.85
2019-12-31
FY2019
$-0.25

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Better Therapeutics, Inc. (BTTX) measures how much investors pay for each dollar of the company's trailing earnings. BTTX's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$1.69.

PE Ratio = Stock Price ÷ EPS (TTM)
= $0.00 ÷ -$1.69 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

BTTX pe ratio · 6 questions

BTTX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.00 and TTM EPS of -$1.69. Data sourced from Financial Modeling Prep via BTTX's SEC 10-K and 10-Q filings.

BTTX PE ratioWhat is BTTX PE ratioCurrent PE ratio of BTTXBTTX PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Better Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08